Enovis (NYSE:ENOV) Given New $45.00 Price Target at Canaccord Genuity Group

Enovis (NYSE:ENOV) had its target price reduced by investment analysts at Canaccord Genuity Group from $50.00 to $45.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s target price would suggest a potential upside of 72.53% from the company’s previous close.

A number of other research analysts have also recently commented on the company. Weiss Ratings upgraded Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. Zacks Research upgraded shares of Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. UBS Group restated a “buy” rating and issued a $51.00 target price (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. BMO Capital Markets reiterated an “outperform” rating and set a $30.00 price target on shares of Enovis in a research report on Friday, August 7th. Finally, Evercore set a $32.00 target price on Enovis in a research note on Monday, July 6th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Enovis presently has a consensus rating of “Moderate Buy” and an average target price of $41.29.

Enovis Stock Up 0.1%

ENOV stock opened at $26.08 on Monday. Enovis has a fifty-two week low of $19.14 and a fifty-two week high of $34.28. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of -1.35 and a beta of 1.34. The business’s fifty day moving average price is $24.89 and its two-hundred day moving average price is $24.03.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The business had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. During the same period last year, the firm earned $0.79 earnings per share. Enovis’s revenue for the quarter was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts anticipate that Enovis will post 3.12 earnings per share for the current year.

Insider Buying and Selling at Enovis

In other news, insider Oliver Engert acquired 1,200 shares of Enovis stock in a transaction that occurred on Thursday, June 11th. The shares were acquired at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the transaction, the insider directly owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. The trade was a 2.37% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders acquired 4,200 shares of company stock worth $92,084. Company insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ENOV. Dimensional Fund Advisors LP boosted its position in Enovis by 1.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company’s stock worth $90,156,000 after buying an additional 51,201 shares during the period. Rubric Capital Management LP acquired a new position in Enovis in the 3rd quarter valued at approximately $83,435,000. Paradigm Capital Management Inc. NY raised its stake in shares of Enovis by 70.2% during the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock valued at $40,420,000 after acquiring an additional 732,917 shares during the last quarter. River Road Asset Management LLC lifted its holdings in shares of Enovis by 3.2% during the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock worth $39,621,000 after purchasing an additional 46,289 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Enovis by 38.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company’s stock worth $24,430,000 after purchasing an additional 287,687 shares during the last quarter. Institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.